7 Mesothelioma Prognostic Factors Ranked by Impact on 2026 Survival Rates

What Are the Key Facts About Mesothelioma Survival and Prognosis?

• Histology is the single strongest mesothelioma prognostic factor: epithelioid median OS 18-24 months versus sarcomatoid 5-8 months under chemotherapy [7].
• Tumor site is the next biggest split: pleural mesothelioma 5-year relative survival is 12 percent (SEER), while peritoneal 5-year survival reaches 65 percent in CRS+HIPEC-eligible patients at high-volume centers [11].
• The CheckMate 743 5-year update (Scherpereel et al, J Clin Oncol 2026) showed 14 percent 5-year overall survival on first-line nivolumab plus ipilimumab versus 6 percent on chemotherapy in unresectable pleural mesothelioma [1].
• Non-epithelioid patients gained the most from immunotherapy: 12 percent 5-year overall survival on nivo+ipi versus 1 percent on chemotherapy — a more than 10-fold relative improvement [1].
• ECOG performance status 0-1 is required for first-line immunotherapy and most clinical trials; ECOG 2 substantially restricts treatment options [2].
• Stage I-II pleural mesothelioma has 2-3 times the median overall survival of stage IV disease [4].
• Treatment at NCI-designated comprehensive cancer centers is associated with 30-70 percent higher 5-year survival than treatment at low-volume centers.
• Biological sex is an independent prognostic factor — women have a survival advantage across multiple population-based cohorts [4].
• Two validated prognostic scoring systems — EORTC and CALGB — combine these factors into risk groups with statistically distinct survival curves [6].
• The PLACE prognostic model (Zhang et al, 2023) gives ECOG status the highest single-variable weight (2 points) and identified a high-risk group with HR 3.878 for shorter survival [10].

What Are the 7 Most Important Prognostic Factors for Mesothelioma?

Mesothelioma prognosis is not one number. Across published cohorts, seven independent variables stretch median overall survival from 5 months at the worst end to over 60 months at the best — a more than 10-fold spread. Each variable has been validated across National Cancer Database (NCDB), SEER, and prospective trial cohorts [4]. The seven factors that consistently emerge are:

1. Histological subtype (epithelioid, biphasic, sarcomatoid)
2. Anatomic site (pleural vs peritoneal — and the rarer pericardial and testicular forms)
3. Stage at diagnosis (TNM 9th edition for pleural; peritoneal cancer index for peritoneal)
4. ECOG performance status (0-4 functional scale)
5. Age at diagnosis
6. Biological sex (women have an independent survival advantage)
7. Treatment center experience (NCI-designated and high-volume specialty centers)

The 2019 review by Carbone and colleagues in CA: A Cancer Journal for Clinicians remains one of the most-cited syntheses of mesothelioma biology and prognosis, and it explicitly frames the disease as the product of a fixed biology — established at the time of asbestos exposure — modulated by treatment access in the present [5]. That distinction matters: patients cannot change their subtype, but they can change where they are treated.

Why Is Histology the Strongest Prognostic Factor for Mesothelioma Survival?

Histological subtype is the single most powerful prognostic discriminator in mesothelioma. The three subtypes — epithelioid, biphasic, and sarcomatoid — are assigned by a pathologist from the diagnostic biopsy and reflect different tumor biology. Across NCDB and Memorial Sloan Kettering cohorts, sarcomatoid histology carries a hazard ratio of 2.22 for death versus epithelioid [7].

Epithelioid mesothelioma accounts for 60-70 percent of cases [5]. Its cells grow in organized sheets and respond comparatively well to chemotherapy, surgery, and immunotherapy. Median overall survival is 18-24 months with multimodal treatment in good-performance-status patients.

Sarcomatoid mesothelioma accounts for 10-15 percent of cases [5]. The cells are spindle-shaped, infiltrate adjacent tissue planes aggressively, and historically responded poorly to platinum-pemetrexed chemotherapy. Median overall survival is 5-8 months under chemotherapy alone [7].

Biphasic mesothelioma contains both epithelioid and sarcomatoid components and falls between the two in prognosis. The proportion of sarcomatoid content within a biphasic tumor predicts how it will behave. (For a dedicated walkthrough of how the three subtypes differ in cell biology and treatment response, see our companion article on epithelioid, sarcomatoid, and biphasic mesothelioma cell types.)

The reason histology dominates prognostic models — including the Contemporary Analysis of Prognostic Factors by Billé and colleagues at Memorial Sloan Kettering [7] — is that it captures a stable biological property of the tumor. Stage and performance status can change over time. Subtype generally does not.

The CheckMate 743 trial complicated the historical picture. In the original 2021 Lancet publication, Baas and colleagues showed that first-line nivolumab plus ipilimumab improved overall survival across the whole study population, but the benefit was largest in non-epithelioid patients [2]. The 2026 5-year update by Scherpereel and colleagues in the Journal of Clinical Oncology confirmed durability of that benefit, with 5-year overall survival of 14 percent on immunotherapy versus 6 percent on chemotherapy [1]. For the first time in the modern era, sarcomatoid and biphasic patients have a treatment with a survival benefit that compares favorably to what epithelioid patients have had for years.

"For decades, a sarcomatoid diagnosis was treated by oncologists almost as a death sentence — there simply was not a regimen that consistently extended life. The CheckMate 743 5-year update is the first time I can sit with a non-epithelioid patient and talk about a real treatment plan rather than a hospice timeline. That is a sea change in this disease."

— David Foster, Executive Director, Danziger & De Llano

How Does Tumor Site (Pleural vs Peritoneal) Predict Mesothelioma Survival Rates?

Pleural and peritoneal mesothelioma behave like two different diseases. SEER puts pleural 5-year relative survival at 12 percent versus peritoneal 5-year survival of 65 percent in CRS+HIPEC-eligible patients — a 5.4-fold gap driven by biology, treatment access, and patient age at diagnosis [11].

Pleural mesothelioma accounts for 85 percent of cases. It typically presents with shortness of breath, pleural effusion, and chest pain. SEER 5-year relative survival is 12 percent across all pleural mesothelioma patients [11]. Median overall survival ranges from 9 to 18 months depending on stage, performance status, and treatment era.

Peritoneal mesothelioma accounts for 10-15 percent of cases. It presents with abdominal pain, distension, and ascites. The signature treatment is cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). In selected patients at high-volume centers, 5-year survival reaches 65 percent — a number unimaginable in pleural mesothelioma [13].

The site difference is not just about surgery access. Peritoneal patients are younger at diagnosis (median age early 60s versus mid 70s for pleural), are more likely to be treated at academic medical centers, and present with disease often confined to the abdomen and amenable to complete cytoreduction. Each factor compounds the survival advantage.

Pericardial mesothelioma (the lining of the heart) and testicular mesothelioma (tunica vaginalis) are far rarer and have distinct prognostic considerations, but they share the same general framework: site shapes both biology and treatment access, which together shape survival.

How Does Stage at Diagnosis Affect Mesothelioma Survival Outcomes?

Stage describes how far the cancer has spread at diagnosis. For pleural mesothelioma, the 9th edition of the TNM staging system (effective 2025) replaced earlier T-category cutoffs with a quantitative measure called Psum — the sum of three pleural-thickness measurements — and added new clinical-T (cT) versus pathological-T (pT) divergence rules. For peritoneal mesothelioma, the peritoneal cancer index (PCI) — a 0-to-39 score based on disease burden in 13 abdominal regions — is the dominant staging metric and the most important predictor of whether cytoreductive surgery can be complete.

For a full breakdown of how the four mesothelioma stages map to treatment options and 5-year survival rates, see our mesothelioma staging guide. Stage I-II pleural mesothelioma carries 2-3 times the median overall survival of stage IV disease. The NCDB analysis by Van Gerwen and colleagues used 16,267 unresectable pleural mesothelioma patients. It confirmed that earlier stage independently predicted longer survival even after controlling for age, sex, histology, and treatment [4].

The practical implication for patients: a stage assigned without a complete workup (PET-CT, surgical staging when indicated, mediastinoscopy in selected cases) is unreliable. The NCI Mesothelioma Treatment PDQ explicitly recommends that staging be performed by a multidisciplinary team experienced in mesothelioma [12], because under-staging can route a patient away from curative-intent surgery, and over-staging can route a patient away from treatment they could in fact tolerate.

Why Do Performance Status, Age, and Sex Each Independently Predict Survival?

Three patient-level variables — performance status, age, and sex — each carry independent prognostic weight. ECOG performance status ≥2 carries a hazard ratio of 5.03 for death versus ECOG 0-1 in a Taiwanese cohort of 93 unresectable pleural mesothelioma patients [8]. The other two variables (age and sex) each add 1.5- to 2-fold independent effects in NCDB analyses [4].

ECOG performance status is a 0-to-4 functional scale that measures whether a patient is fully active (0), restricted from strenuous activity (1), ambulatory but unable to work (2), capable of only limited self-care (3), or completely bedridden (4). It is the gating eligibility criterion for most clinical trials, and for first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma, an ECOG of 0 or 1 was required for enrollment. (See our dedicated article on how ECOG performance status shapes mesothelioma treatment eligibility for the full scoring framework.) The Steele et al review in Lung Cancer in 2005 — and many cohorts since — confirmed that performance status retains independent prognostic power even when histology, stage, and laboratory values are taken into account [8].

Both validated prognostic scoring systems — the European Organisation for Research and Treatment of Cancer (EORTC) system and the Cancer and Leukemia Group B (CALGB) system — include performance status as a core variable. Edwards and colleagues at Leicester validated both systems in 142 patients and demonstrated that survival curves separated cleanly by risk group [6].

Age at diagnosis predicts survival in part because of biology (older patients tolerate aggressive multimodal therapy less well) and in part because of access (older patients are less often referred for cytoreductive surgery or aggressive immunotherapy). NCDB analyses consistently show younger age as an independent predictor of longer survival.

Sex is an independent prognostic factor in mesothelioma — and one that surprises many patients. Women have better overall survival across multiple SEER and population-based cohorts even after adjusting for histology, stage, and treatment. Proposed explanations include differences in asbestos exposure intensity (men more often had occupational, high-dose exposure), differences in immune response, and possible hormonal influences. Whatever the mechanism, biological sex is a real prognostic variable, not an artifact of confounding.

How Much Does Treatment Center Volume Improve Mesothelioma Survival?

Treatment center experience is the most modifiable of the seven prognostic factors. NCDB analyses show patients at high-volume, NCI-designated comprehensive cancer centers have 30-70 percent higher 5-year survival than patients at low-volume community centers. Mesothelioma sits at the higher end of that range because of its rarity and the technical complexity of its treatments.

The mechanism is straightforward. CRS+HIPEC for peritoneal disease, extended pleurectomy/decortication for pleural disease, immunotherapy management, and multimodal sequencing all depend on team experience that only accumulates with case volume. The MARS2 trial — Lim and colleagues, Lancet Respiratory Medicine, 2024 — illustrated how center-level outcomes diverge. Extended pleurectomy/decortication produced worse 2-year outcomes than chemotherapy alone in the trial setting. Observational data from specialized centers continued to show favorable results, suggesting that selection and technique matter as much as the procedure itself [3].

The 2025 systematic review and meta-analysis by Skelin and colleagues pooled 7 randomized clinical trials and 2,549 patients. It reported a hazard ratio of 0.78 for overall survival favoring immunotherapy across ECOG groups [9]. The trial populations were drawn predominantly from high-volume academic centers, so real-world replication depends on whether patients can reach centers that routinely manage the regimens.

"The single most consequential decision a newly diagnosed mesothelioma patient makes is not which surgery to choose or which drug to start — it is which center to walk into for the workup. We have seen patients told they were inoperable at a community hospital who were taken to surgery successfully at a high-volume program two weeks later. The same disease, the same patient, two different prognoses."

— David Foster, Executive Director, Danziger & De Llano

How Has Immunotherapy Changed Long-Term Survival Outcomes Since 2020?

The FDA approval of nivolumab plus ipilimumab as first-line treatment for unresectable pleural mesothelioma in October 2020 reset prognostic expectations for the largest subset of patients. The 2021 Lancet publication by Baas and colleagues — the CheckMate 743 primary analysis — reported median overall survival of 18.1 months on immunotherapy versus 14.1 months on platinum-pemetrexed chemotherapy [2].

The 5-year follow-up — Scherpereel and colleagues, Journal of Clinical Oncology, 2026 — confirmed that the early survival benefit translated into long-term durability. The 5-year overall survival rate was 14 percent on nivolumab plus ipilimumab versus 6 percent on chemotherapy [1]. In the non-epithelioid subgroup (biphasic and sarcomatoid combined), 5-year overall survival was 12 percent on immunotherapy versus 1 percent on chemotherapy — a more than 10-fold relative improvement in a group that historically had the worst prognosis.

What immunotherapy has not changed is the underlying biology that drives prognosis. Histology, site, stage, and performance status still rank patients into prognostic groups in the same order they did before 2020. What has changed is the ceiling. A 5-year survivor of unresectable pleural mesothelioma is no longer a statistical outlier — at 14 percent on immunotherapy, that outcome is the realistic upper end of the modern survival curve for the disease.

What Do Mesothelioma Prognostic Scoring Systems Predict?

Two prognostic scoring systems are validated for mesothelioma and remain in regular clinical use.

The EORTC system divides patients into good-prognosis and poor-prognosis groups based on five variables: performance status, histology, biological sex, white blood cell count, and whether the diagnosis is definite (vs probable). The CALGB system uses six variables — ECOG status, age, hemoglobin, white blood cell count, presence of chest pain, and pleural histology — to classify patients into six prognostic groups.

The Edwards et al validation study in Thorax in 2000 demonstrated that both systems successfully stratified mesothelioma patients into groups with statistically distinct survival curves [6]. More recent additions include the PLACE prognostic model, developed by Zhang and colleagues in 2023 and published in BMC Cancer, which gives ECOG status the highest individual weight in the score (2 points) — more than age, platelet count, lymphocyte count, or calcium levels — and identified high-risk patients with a hazard ratio of 3.878 for shorter survival [10].

These scoring systems are most useful for clinical trial stratification and for prognosis conversations that need to communicate ranges rather than point estimates. They describe groups, not individuals. A 2026 patient's outlook is also shaped by access to immunotherapy and to a high-volume specialty center — modifiable factors that the older scoring systems were not designed to capture.

What Should Patients Do With This Information?

Three concrete steps shift the prognostic odds. The 30-70 percent survival advantage at NCI-designated centers is the single largest modifiable factor a newly diagnosed patient can act on in the first 30 days [12].

1. Confirm histology and stage with a multidisciplinary team. A pathology second opinion at a high-volume mesothelioma center is reasonable for any newly diagnosed patient, because subtype assignment and staging both directly determine the treatment plan. The NCI PDQ explicitly recommends multidisciplinary review [12].

2. Get a referral to a specialty center before locking in a treatment plan. The 30-70 percent survival advantage at NCI-designated comprehensive cancer centers is not theoretical — it shows up in registry data across procedures. Travel for an in-person evaluation is often the highest-yield action a patient can take in the first month after diagnosis. Treatment can still be delivered closer to home.

3. Pursue your legal and financial options in parallel with treatment. Mesothelioma is, in nearly every case, the result of asbestos exposure that an employer or product manufacturer was responsible for. Compensation through asbestos trust funds and personal injury claims funds the cost of specialty-center care, immunotherapy out-of-pocket costs, travel, lost wages, and family support. Statutes of limitations are short — typically 1-3 years from diagnosis depending on state. The legal process runs on a separate timeline from the medical one.

"Every patient I work with is balancing two clocks: the medical one and the legal one. Both are unforgiving, and both reward early action. The patients who do best — both medically and financially — are the ones who line up a high-volume specialty center and a mesothelioma-experienced attorney in the same week. Neither decision can wait for the other."

— David Foster, Executive Director, Danziger & De Llano

References

1. Scherpereel A, Baas P, Nowak AK, Tsao AS, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol. 2026. PMID: 41734361.
2. Baas P, Scherpereel A, Nowak AK, Fujimoto N, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID: 33485464.
3. Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS2): a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2024. PMID: 38740044.
4. Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40(4):529-536. PMID: 30649229.
5. Carbone M, Adusumilli PS, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-429. PMID: 31283845.
6. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731-735. PMID: 10950889.
7. Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2016;11(2):249-255. PMID: 26845118.
8. Steele JPC, Klabatsa A, Fennell DA, et al. Prognostic factors in mesothelioma. Lung Cancer. 2005;49(Suppl 1):S49-S52. PMID: 15894403.
9. Skelin M, Matić K, Anić-Matić A, et al. Immunotherapy in mesothelioma — systematic review and meta-analysis. J Chemother. 2025;38(3):290-301. PMID: 40264298.
10. Zhang Y, Li N, Li R, Gu Y, Liu X, Zhang S. Predicting survival for patients with mesothelioma: development of the PLACE prognostic model. BMC Cancer. 2023;23(1):698. PMID: 37495975.
11. National Cancer Institute. SEER Cancer Statistics Explorer: Mesothelioma. seer.cancer.gov. Accessed 2025.
12. National Cancer Institute. Mesothelioma Treatment (PDQ) – Health Professional Version. cancer.gov. Updated 2026.
13. WikiMesothelioma. Peritoneal Mesothelioma — survival and CRS-HIPEC outcomes. wikimesothelioma.com/Peritoneal_Mesothelioma.